Revance Therapeutics Priced, Nasdaq: RVNC
Clinical-stage biotech developing a non-injectable formulation of botulinum toxin.
Industry: Health Care
First Day Return: +67.8%
Industry: Health Care
RVNC
Clinical-stage biotech developing a non-injectable formulation of botulinum toxin.
| IPO Data | |
|---|---|
| IPO File Date | 12/31/2013 |
| Offer Price | $16.00 |
| Price Range $14.00 - $16.00 | |
| Offer Shares (mm) | 6.0 |
| Deal Size ($mm) | $96 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 02/05/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $96 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Newark, CA, United States |
| Founded | 1999 |
| Employees at IPO | 64 |
| Website www.revance.com | |
IPO News for Revance Therapeutics
Revance Therapeutics (RVNC) Performance
